Human study PLS-00049

AGEs-RAGE Axis and Mitochondrial-Derived Peptides in Advanced Chronic Kidney Disease: Interconnected Pathways Beyond Inflammation and Nutrition.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

AGEs-RAGE Axis and Mitochondrial-Derived Peptides in Advanced Chronic Kidney Disease: Interconnected Pathways Beyond Inflammation and Nutrition.primary · Antioxidants (Basel, Switzerland) · 2026-07-30 · PMID 42650220 · DOI

Design and participants

Design: Cross-sectional study
Population: Adults with kidney failure undergoing living-donor kidney transplantation, and controls
Conditions: Chronic kidney disease, Kidney failure
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): CKD shows increased glycoxidative stress and reduced mitochondrial-derived peptides, reflecting altered mitochondrial stress signaling. AGEs-RAGE and MDPs appear biologically linked through partially overlapping but distinct pathways.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

inappropriate population: Endogenous MOTS-c levels were measured. No one received MOTS-c, so the study cannot inform the effects of giving the compound.
abstract only: Only the abstract is available in the record. Methods, numbers and statistics are not fully reported.
inappropriate endpoint: Endogenous peptide levels were measured as biomarkers; no MOTS-c was administered and no clinical outcomes were assessed.
confounding: The cross-sectional design with correlational analyses cannot establish causality, and the adjustment set is not described in the abstract.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves metabolic health: not eligible (not primary study) for “Insulin sensitivity, glucose control or body weight”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 42650220, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 42650220, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 42650220, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).